The future of biological therapy: a pathway forward for biosimilars
Journal Title: Generics and Biosimilars Initiative Journal - Year 2013, Vol 2, Issue 1
Abstract
Biologicals are advanced prescription drugs to treat cancer, rheumatoid arthritis HIV/AIDS, multiple sclerosis and other debilitating diseases. In November 2010, the US Food and Drug Administration (FDA) began consultation with patient groups, physicians and industry on how to approve the first copies of these drugs, known as follow-on biologics in the US or biosimilars. As FDA moves forward in implementing this pathway, it is essential that all stakeholders work together to ensure patient safety remains the top priority to achieve safe and efficacious patient care.
Authors and Affiliations
Richard O Dolinar, Michael S Reilly
Keywords
Related Articles
- EP ID EP355101
- DOI 10.5639/gabij.2013.0201.014
- Views 90
- Downloads 0
Current status of biopharmaceuticals in Iran’s pharmaceutical market
The clinical importance of biopharmaceuticals for the management of life threatening diseases is increasing but costs have become a major obstacle to the administration of these medicines, especially in resource limited...
IAPO launched the Patient-Centred Healthcare Indicators Review
In October 2012, the International Alliance of Patients’ Organizations (IAPO) launched its final Patient-Centred Healthcare Indicators Review and accompanying consultation report [1]. The review forms the initial stage o...
The ethics of biosimilars
Comment on the Letters to the Editor by Dr Carlo Petrini: A bioethicist’s view of the use of biosimilars, published in GaBI Journal, 2012, issue 3-4.
Biosimilar monoclonal antibodies—challenges and opportunities in Europe
New regulations for the development of biosimilars have been introduced in Europe and a new class of biosimilars – monoclonal antibodies – is expected on the market soon, which will both challenge and benefit our healthc...
The MEDICRIME Convention: criminalising the falsification of medicines and similar crimes
Trade in falsified/counterfeit medical products is a growing global criminal industry, posing a major threat to patients and healthcare systems. Falsified/Counterfeit medical products circulate via unregulated channels,...